Author

Anke E Kip

Observed names: A. E. Kip, A.E. Kip, Anke E. Kip, Anke Kip, Kip, A., Kip, Anke

Institution: Lygature

Observed institutions: Utrecht University, Slotervaartziekenhuis, The Netherlands Cancer Institute, Lygature

ORCID: 0000-0002-7093-8075

Observed ORCID: 0000-0002-7093-8075

OpenAlex ID: A5043714917

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

2016 · Monique Wasunna, Simon Njenga, et al. · PLoS neglected tropical diseases · 112

PDF

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

2019 · Barbara Willekens, Silvia Presas-Rodríguez, et al. · BMJ Open · 107

PDF

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

2017 · Anke E. Kip, Jan H. M. Schellens, et al. · Clinical Pharmacokinetics · 93

PDF

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples

2016 · A.E. Kip, K.C. Kiers, et al. · Journal of Pharmaceutical and Biomedical Analysis · 81

PDF

Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis

2014 · Anke E. Kip, Manica Balasegaram, et al. · Antimicrobial Agents and Chemotherapy · 72

PDF

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis

2016 · María del Mar Castro, Maria Adelaida Gomez, et al. · Antimicrobial Agents and Chemotherapy · 61

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial

2018 · Jane Mbui, Joseph Olobo, et al. · Clinical Infectious Diseases · 59

PDF

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

2017 · Thomas P C Dorlo, Anke E Kip, et al. · Journal of Antimicrobial Chemotherapy · 37

PDF

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa

2021 · Luka Verrest, Anke E Kip, et al. · Clinical Infectious Diseases · 35

PDF

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection

2016 · A. E. Kip, H. Rosing, et al. · Antimicrobial Agents and Chemotherapy · 22

PDF

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa

2020 · Semra Palić, Anke E Kip, et al. · Journal of Antimicrobial Chemotherapy · 21

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis

2018 · Anke E. Kip, Monique Wasunna, et al. · Frontiers in Cellular and Infection Microbiology · 19

PDF

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure–response relationships

2018 · Anke E Kip, María del Mar Castro, et al. · Journal of Antimicrobial Chemotherapy · 18

PDF

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry

2015 · A.E. Kip, H. Rosing, et al. · Journal of Chromatography B · 17

PDF

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study

2021 · Anke E Kip, Séverine Blesson, et al. · Journal of Antimicrobial Chemotherapy · 13

PDF

Road to FAIR genomes: a gap analysis of NGS data generation and sharing in the Netherlands

2022 · Jeroen A M Belien, Anke E Kip, et al. · BMJ Open Science · 10

PDF

Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages

2016 · Luuk C.T. Dohmen, Adriana Navas, et al. · Journal of Biological Chemistry · 10

PDF

Towards a dendritic cell-based vaccine for the treatment of multiple sclerosis (MS): interim safety data of the first dose cohort of the MS-tolDC phase I clinical trial

2018 · Nathalie Cools, Silvia Presas-Rodríguez, et al. · Frontiers in Neuroscience · 2

Safety and feasibility of a tolerogenic dendritic cell-based treatment of multiple sclerosis (MS): a collaborative initiative comparing intranodal and intradermal cell administration in two phase I clinical trials

2018 · Willekens, B., Presas-Rodriguez, S., et al. · Document Server@UHasselt (UHasselt) · 1

Tolerogenic dendritic cell-based treatment in multiple sclerosis (MS): Interim results of two phase I clinical trials. (P3.2-047)

2019 · Silvia Presas-Rodríguez, Barbara Willekens, et al. · Neurology

Tolerogenic dendritic cell-based treatment in multiple sclerosis (MS): Interim results of two phase I clinical trials

2019 · Presas-Rodriguez, Silvia, Willekens, Barbara, et al. · Document Server@UHasselt (UHasselt)

Clinical pharmacology and bioanalysis of antileishmanial drugs : Towards improved treatment strategies for leishmaniasis

2017 · Anke E Kip · Utrecht University Repository (Utrecht University)

Works count: 25

Citation count: 790

H-index: 14

I10-index: 17